Neumora Therapeutics, Inc.
NMRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001885522
In the last 90 days, Neumora Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $129.2M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Neumora Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- +12 vs. Q2 2024
- Shares held
- 68.7M
- +9.45M (+16.0%) vs. Q2 2024
- Total value
- $907.0M
- +$324.8M (+55.8%) vs. Q2 2024
- New holders
- 23
- 34 more added
- Sold out
- 11
- 22 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NMRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 113 | $129.2M |
| Q1 2026 | 114 | $137.2M |
| Q4 2025 | 102 | $112.7M |
| Q3 2025 | 93 | $92.2M |
| Q2 2025 | 98 | $41.1M |
| Q1 2025 | 116 | $65.2M |
| Q4 2024 | 135 | $851.6M |
| Q3 2024 | 104 | $907.0M |
| Q2 2024 | 93 | $627.4M |
| Q1 2024 | 88 | $725.4M |
| Q4 2023 | 60 | $744.8M |
| Q3 2023 | 38 | $512.0M |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Neumora Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 5,228,333 | $69.1M | 0.04% | +127,237+2.5% | Added |
| BlackRock, Inc. | 6,186,894 | $81.7M | 0.00% | +6,186,894 | New |
| Softbank Group Corp | 7,546,916 | $99.7M | 0.45% | −100,000−1.3% | Reduced |
| FMR LLC | 7,749,156 | $102.4M | 0.01% | −873,312−10.1% | Reduced |
| Artal Group S.A. | 0 | $0 | 0.00% | −2,824,052−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −380,160−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −295,973−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −134,545−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −65,728−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −45,000−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −32,500−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −30,800−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −25,756−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −16,878−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −5,221−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |